Peptide Receptor Radionuclide Therapy for Refractory Mid-Gut Neuroendocrine Tumors

A new study supports prior findings that progression-free survival, but not overall survival, is superior with PRRT versus systemic therapy.

Peptide receptor radionuclide therapy (PRRT) is approved to treat well-differentiated, midgut neuroendocrine tumors after progression on somatostatin analogue (SSA) therapy, based on improved progression-free survival (PFS) observed in the NETTER-1 trial (NEJM JW Oncol Hematol Mar 2017 and N Engl J Med 2017; 376:125). Approval for the therapy was then extended to treat low- or intermediate-grade gastroenteropancreatic neuroendocrine tumors. However, an update of the NETTER-1 trial did not indicate superior overall survival (OS) with PRRT versus escalated-dose SSA in patients with refractory midgut neuroendocrine tumors (NEJM JW Oncol Hematol Feb 2022 and Lancet Oncol 2021; 22:1752).

Now, Italian investigators report results of a multicenter,…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

Peptide Receptor Radionuclide Therapy for Refractory Mid-Gut Neuroendocrine Tumors

Topics

Reviewing Author